Ocugen, Inc. Announces Proposed Public Offering of Common Stock
23 Maio 2023 - 5:01PM
Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on
discovering, developing, and commercializing novel gene and cell
therapies, biologics, and vaccines, today announced that it has
commenced an underwritten public offering of its common stock. In
addition, Ocugen expects to grant to the underwriter a 30-day
option to purchase up to an additional 15% of shares of the common
stock sold in the public offering. All of the securities in the
offering are to be sold by Ocugen. The offering is subject to
market and other customary closing conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Ocugen intends to use the net proceeds of the proposed offering
for general corporate purposes, capital expenditures, working
capital, and general and administrative expenses.
Cantor Fitzgerald & Co. is acting as the sole book-running
manager for the offering.
The offering is being made by Ocugen pursuant to a shelf
registration statement on Form S-3 previously filed with the
Securities and Exchange Commission (the “SEC”) on February 28,
2023, which became effective on April 21, 2023. A preliminary
prospectus supplement related to the offering will be filed with
the SEC and will be available on the website of the SEC at
www.sec.gov. Copies of the preliminary prospectus supplement and
accompanying base prospectus relating to this offering may be
obtained, when available, from Cantor Fitzgerald & Co., Attn:
Capital Markets, 499 Park Avenue, 4th floor, New York, NY 10022;
Email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, which are subject to risks and uncertainties. Such
forward-looking statements within this press release include,
without limitation, statements regarding market conditions, the
completion of the proposed offering, the satisfaction of customary
closing conditions related to the proposed offering and the
intended use of net proceeds from the proposed offering. There can
be no assurance that we will be able to complete the proposed
public offering on the anticipated terms, or at all. We may, in
some cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from our
current expectations, such as market and other conditions. These
and other risks and uncertainties are more fully described in our
periodic filings with the SEC, including the risk factors described
in the section entitled “Risk Factors” in the quarterly and annual
reports that we file with the SEC. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Ocugen Contact:
Tiffany HamiltonHead of Corporate Communications
Tiffany.Hamilton@Ocugen.com
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024